Key result
Significant TR after STEMI linked to ~2.8-fold higher long-term all-cause mortality.
Why the study?
Risk stratification after STEMI primarily focuses on LVEF and ischemic mitral regurgitation, whereas the prognostic significance of tricuspid regurgitation after left-sided STEMI remains poorly defined.
Does the presence of moderate or severe tricuspid regurgitation within 24 hours of primary PCI increase the risk of long-term all-cause mortality in patients presenting with a first left-sided (LAD or LCX) STEMI?
Cohort (n=1,273)
No
Does the presence of moderate or severe tricuspid regurgitation within 24 hours of primary PCI increase the risk of long-term all-cause mortality in patients presenting with a first left-sided (LAD or LCX) STEMI?
Moderate or greater tricuspid regurgitation detected within 24 hours of primary PCI for left-sided STEMI occurs in 5.8% of patients and independently predicts nearly a threefold increase in long-term all-cause mortality, even among those with preserved LVEF.
May refine post-STEMI risk stratification beyond LVEF; leaves open whether TR-targeted interventions improve outcomes.
Background Risk stratification for patients with ST-elevation myocardial infarction (STEMI) primarily focuses on left ventricular ejection fraction (LVEF) and ischemic mitral regurgitation (MR), whereas the prognostic significance of tricuspid regurgitation (TR) after left-sided STEMI remains poorly defined. Methods We retrospectively analyzed consecutive patients presenting with a first LAD- or LCX-related STEMI between 2000 and 2019 who underwent primary percutaneous coronary intervention (PCI). Patients with prior myocardial infarction, revascularization, or significant valvular disease were excluded. Transthoracic echocardiography was performed within 24 h of PCI. Significant TR was defined as at least moderate regurgitation. The primary endpoint was long-term all-cause mortality. Results Among 1,273 patients with left-sided STEMI, moderate or severe TR was present in 74 patients (5.8%). Patients with significant TR had higher all-cause mortality (44.6% vs. 10.8%; p < 0.001), in-hospital mortality (12.2% vs. 1.9%; p < 0.001), and 1-year major adverse cardiovascular events (39.2% vs. 15.3%; p < 0.001). Kaplan-Meier analysis demonstrated significantly lower long-term survival among patients with significant TR (log-rank p < 0.001). After adjustment for age, comorbidities, infarct size, LVEF, MR, and right ventricular dysfunction (RVD), TR remained independently associated with mortality (HR 2.84, 95% CI 1.43–5.6; p = 0.002). Propensity score-matched analysis confirmed these findings. Importantly, TR remained associated with higher long-term all-cause mortality even among patients with preserved LVEF (27.3% vs. 3.7%; p = 0.011). Conclusions Moderate or greater TR after left-sided STEMI is independently associated with adverse outcomes beyond those attributable to reduced LVEF and MR. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Guz et al. (2026) conducted a cohort in First LAD- or LCX-related ST-segment elevation myocardial infarction (STEMI) (n=1,273). Moderate or severe tricuspid regurgitation (TR) vs. No or mild tricuspid regurgitation (TR) was evaluated on Long-term all-cause mortality (HR 2.84, 95% CI 1.43-5.6, p=0.002). Moderate or severe tricuspid regurgitation after left-sided STEMI was independently associated with higher long-term all-cause mortality compared to no or mild TR (44.6% vs 10.8%; HR 2.84, p=0.002).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: